medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2010, Number 05

<< Back Next >>

Ginecol Obstet Mex 2010; 78 (05)

Alpha-fetoprotein as an early predictor of adverse perinatal outcome

García-Cavazos R, Colín-Valenzuela A, Espino SS

Language: Spanish
References: 25
Page: 268-274
PDF size: 317.63 Kb.


ABSTRACT

Background: The alpha-fetoprotein (AFP) is a glycoprotein, which is produced by the human fetus. Previous studies have shown associations between elevated AFP levels and an increased risk of adverse perinatal outcomes.
Objective: To determine if abnormal AFP levels are associated with adverse perinatal outcomes. The AFP concentrations were calculated as Multiples of the medians (MoM).
Patients and method: A prospective cohort study, including 283 pregnant women, the maternal serum concentration of AFP was determined between 15 and 20 weeks of pregnancy, and the pregnancy was followed until term, when we search for the perinatal outcomes. The study was made in the Instituto Nacional de Perinatología, in Mexico City, from August 2007 to January 2008. For the analyses, the AFP concentrations were calculated as Multiples of the medians (MoM).
Results: The threshold of 1.5 MoM increases the risk for preterm delivery (RR: 1.77, IC 95%: 1.04-3.03), abruption placentae (RR: 3.67, IC 95%: 1.59-8.49), placenta accreta (RR: 3.67, IC 95%: 1.59-8.49) and for intrauterine growth restriction (RR: 2.86, IC 95%: 1.74-4.68) There was a weak relation between AFP concentration and birth weight (r = -0.12, p = 0.047) and no correlation with pregnancy weeks at birth.
Conclusions: There is a relation between adverse perinatal outcome and abnormal AFP levels. The evidence of an increase in the AFP concentration in fetuses without congenital defects should alert de clinician about the possibility of other adverse perinatal outcomes and those results must be included in the prenatal risk assessment.


REFERENCES

  1. Mizejewski GJ. Levels of alpha-fetoprotein during pregnancy and early infancy in normal and disease states. Obstet Gynecol Surv 2003;58:804-826.

  2. Lau HL, Linkins SE. Alpha-fetoprotein. Am J Obstet Gynecol 1976;124:533-554.

  3. Gitlin D. Normal biology of alpha-fetoprotein. Part I. Biology of alpha-fetoprotein. Ann N Y Acad Sci 1975;259:7-16.

  4. Haddow JE, Macri JN, Munson M. The amnion regulates movement of fetally derived alpha-fetoprotein into maternal blood. J Lab Clin Med 1979;94:344-347.

  5. Gitlin D, Perricelli A, Gitlin GM. Synthesis of alpha-fetoprotein by liver, yolk sac, and gastrointestinal tract of the human conceptus. Cancer Res 1972;32:979-982.

  6. Salazar R, Ibarra AL, Iduma M, Leyva R. Especificidad de marcadores bioquímicos del segundo trimestre de embarazo. Ginecol Obstet Mex 2007;75:608-614.

  7. Gitlin D, Boesman M. Serum alpha-fetoprotein, albumin, and gamma-G-globulin in the human conceptus. J Clin Invest 1966;45:1826-1838.

  8. Clarke PC, Gordon YB, Kitau MJ, et al. Alpha-fetoprotein levels in pregnancies complicated by gastrointestinal abnormalities of the fetus. Br J Obstet Gynaecol 1977;84:285-289.

  9. Thomas RL, Blakemore KJ. Evaluation of elevations in maternal serum alpha-fetoprotein: a review. Obstet Gynecol Surv 1990;45:269-283.

  10. Hernández L, Rodríguez A, Hernández J, Rodríguez L. Niveles bajos de alfafetoproteína en suero materno como indicador de riesgo perinatal. Rev Cubana Obstet Ginecol 1997;23:108-114.

  11. Wilkins-Haug L. Unexplained elevated maternal serum alphafetoprotein: what is the appropriate follow-up? Curr Opin Obstet Gynecol 1998;10:469-474.

  12. Baschat AA, Harman CR, Farid G, et al. Very low secondtrimester maternal serum alpha-fetoprotein: Associations whit high birth weight. Obstet Gynecol 2002;99:531-536.

  13. Cho S, Durfee KK, Keel BA, Parks LH. Perinatal outcomes in a prospective matched pair study of pregnancy and unexplained elevated or low AFP screening. J Perinat Med 1997;25:476-483.

  14. Simpson JL, Palomaki GE, Mercer B, et al. Associations between adverse perinatal outcome and serially obtained second- and third-trimester maternal serum alpha-fetoprotein measurements. Am J Obstet Gynecol 1995;173:1742-1748.

  15. Waller DK, Lustig LS, Cunningham GC, et al. The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet Gynecol 1996;88:816-822.

  16. Pahal GS, Jauniaux E. Maternal serum biochemical screening for pregnancy complications other than aneuploidy. Curr Opin Obstet Gynecol 1997;9:379-386.

  17. Huang T, Owolabi T, Summers AM, et al. The identification of risk of spontaneous fetal loss through second-trimester maternal serum screening. Am J Obstet Gynecol 2005;193:395-403.

  18. Krause TG, Christens P, Wohlfahrt J, et al. Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcome. Obstet Gynecol 2001;97:277-282.

  19. Dugoff L, Hobbins JC, Malone FD, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 2005;106:260-267.

  20. Smith GC, Shah I, Crossley JA, et al. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol 2006;107:161-166.

  21. Gordon YB, Lewis JD, Leighton M, et al. Maternal serumalpha-fetoprotein levels as an index of fetal risk. Am J Obstet Gynecol 1979;133:422-424.

  22. Smith ML. Raised maternal serum alpha-fetoprotein levels and low birth weight babies. Br J Obstet Gynaecol 1980;87:1099-1102.

  23. Mariona FG, Hassan MM, Syner FN, et al. Maternal serum alpha-fetoprotein (MSAFP) and fetal growth. J Perinat Med 1984;12:179-183.

  24. Katz VL, Chescheir NC, Cefalo RC. Unexplained elevations of maternal serum alpha-fetoprotein. Obstet Gynecol Surv 1990;45:719-726.

  25. Crandall BF, Robinson L, Grau P. Risks associated with an elevated maternal serum alpha-fetoprotein level. Am J Obstet Gynecol 1991;165:581-586.




2020     |     www.medigraphic.com